A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/52 (2006.01) A61K 31/35 (2006.01) A61K 31/415 (2006.01) A61K 31/50 (2006.01) A61K 31/505 (2006.01)
Patent
CA 2295616
The present invention pertains to the use of inhibitors of phosphodiesterase I, IV and V for the prophylaxis and treatment of prostatic diseases, in particular the use of a) 2-(2-propoxy- phenyl)-8- azapurin-6-one (zaprinast); b) dipyridamole; c) 1-(3-chloropheny-lamino)-4-phenylphthalazine (M5445); d) 2-(N-(4- carboxypiperidine-6-chloro-4-(3,4-(methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355); e) 2,3-dihydro-8- hydroxy-7-nitro-1, 4-benzodioxine-2- methanol, alpha-nitrate (E 4701); f) 4-((3,4-(methylendioxy) benzyl)amino)-6, 7,8-trimethoxy-quinazoline; g) 1-methyl-3-propyl-6- (5-(N-(4- methylmorpholino) sulfonyl)-2-ethoxyphenyl)pyrazole [4,5]pyrimidin-4(5H)one (sildenafil); i) 1-cyclopentyl-3-methyl-6- (4- pyridinyl)pyrazolo(3, 4-d)pyrimidin-4(5H)-one (WIN 58237); j) 7-(3-(4-acetyl-3- hydroxy-2-propyl-phenoxy) -2-hydroxy-propoxy)-2-carboxy- 2, 3-didehydro-chronan-4-one (FPL-557212); k) quinazolines and their trimethoxy derivatives; 1) Pyrazolopyrimidones; as well as pharmacologically compatible salts thereof, quinazolines and their trimethoxy derivatives, pyrazolopyrimidones or compatible salts thereof, in local and systemic administration.
L'invention concerne l'utilisation d'inhibiteurs de la phosphordiestérase I, IV et V pour la prévention et le traitement de maladies de la prostate, plus particulièrement l'utilisation de a) 2- (2-propoxy-phényl)-8-azapurin-6-one (zaprinast); b) dipyridamole; c) 1-(3-chlorophénylamino)-4-phénylphtalazine (M5445); d) 2-(N-(4-carboxypipéridine-6-chloro-4-(3,4-(méthylène-dioxy)benzyl)amino)qinazoline (E 4021, ER 21355); e) 2,3-dihydro-8- hydroxy-7-nitro-1, 4-benzodioxine-2-méthanol, alpha-nitrate (E 4701); f) 4-((3,4-(méthylènedioxy) benzyl)amino)-6, 7,8-triméthoxy-quinazoline; g) 1-méthyl-3-propyl-6- (5-(N-(4-méthylmorpholino) sulfonyl)-2-éthoxyphényl)pyrazole [4,5]pyrimidine-4(5H)one (sildenafil); i) 1-cyclopentyl-3-méthyl-6- (4-pyridinyl)pyrazolo (3, 4-d)pyrimidine-4(5H)one (WIN 58237); j) 7-(3-(4-acétyl-3- hydroxy-2-propyl-phénoxy) -2-hydroxy-propoxy)-2-carboxy-2, 3-didéhydro-chromane-4-one (FPL-557212); k) quinazolines et leur dérivés triméthoxy; l) pyrazolopyrimidones; ainsi que leurs sels pharmaceutiquement compatibles, des quinazolines et leur dérivés triméthoxy, des pyrazolopyrimidones ou leurs sels compatibles pour une administration locale et par voie générale.
Jonas Udo
Stief Christian Georg
Truss Michael Carsten
Uckert Stefan
Forssmann Wolf-Georg
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Use of phosphodiesterase inhibitors in the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of phosphodiesterase inhibitors in the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of phosphodiesterase inhibitors in the treatment of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1416533